Pneumococcal 24-Valent Conjugate Vaccine Gets Fast Track Designation
VAX-24 is an investigational 24-valent pneumococcal conjugate vaccine.
Pneumonia
Inhaled Nitric Oxide May Ease Severe COVID-19 Pneumonia in Pregnant Women
High-dose inhaled nitric oxide linked to more days free from oxygen supplementation, shorter ICU and hospital length of stay
Pneumococcal 15-Valent Conjugate Vaccine Approved for Pediatric Use
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
Point-of-Care Lung Ultrasound Feasible for Pneumonia Diagnosis in Primary Care
Short training program appears sufficient and little time is needed to perform the scan in practice
Pneumococcal 21-Valent Conjugate Vaccine Gets Breakthrough Therapy Status
The designation was based on data from a phase 1/2 study that evaluated a single intramuscular injection of V116 in pneumococcal-naïve adults.
ACIP: 2022 Adult Immunization Schedule Updates
The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes.
Recommendations Simplified for Pneumococcal Vaccination
ACIP recommends PCV20 alone or PCV15 in series with PPSV23 for all aged 65 years and older or younger adults at risk
Shorter Antibiotic Course Safe, Effective for Uncomplicated Childhood CAP
The randomized, double-blind, placebo-controlled study included a total of 380 patients aged 6 to 71 months with nonsevere CAP.
Study Supports Coadministration of Prevnar 20 With Pfizer-BioNTech COVID-19 Vaccine
The randomized, double-blind study recruited adults from the phase 3 Pfizer-BioNTech COVID-19 vaccine trial.
Pneumococcal 15-Valent Conjugate Vaccine Gets Priority Review for Pediatric Use
The application is supported by data from phase 2 and phase 3 clinical studies that assessed the efficacy and safety of Vaxneuvance in infants, children, and adolescents.
